Clinical Policy: Polatuzumab Vedotin-piiq (Polivy)

Reference Number: LA.PHAR.433
Effective Date:
Last Review Date: 07.20.23
Line of Business: Medicaid

Coding Implications
Revision Log

See Important Reminder at the end of this policy for important regulatory and legal information.

Please note: This policy is for medical benefit

Description
Polatuzumab vedotin-piiq (Polivy™) is a CD79b-directed antibody-drug conjugate with activity against dividing B cells.

FDA Approved Indication(s)
Polivy is indicated:

- In combination with bendamustine and a rituximab product for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS), after at least two prior therapies.
- In combination with a rituximab product, cyclophosphamide, doxorubicin, and prednisone (R-CHP) for the treatment of adult patients who have previously untreated diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS) or high-grade B-cell lymphoma (HGBL) and who have an International Prognostic Index score of 2 or greater.

Policy/Criteria
Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.

It is the policy of Louisiana Healthcare Connections® that Polivy is **medically necessary** when the following criteria are met:

I. Initial Approval Criteria

A. Diffuse Large B-Cell Lymphoma (must meet all)**:**

1. Diagnosis of one of the following (a or b):
   a. Previously untreated DLBCL (*see subtypes at Appendix D*);
   b. Relapsed or refractory DLBCL after ≥ 1 prior therapy *(see Appendix B*);
2. Prescribed by or in consultation with an oncologist or hematologist;
3. Age ≥ 18 years;
4. Member is not a candidate for allogeneic or autologous stem cell transplant;
5. Polivy is prescribed as a single agent or in combination with one of the following regimens (a or b):
   a. Bendamustine* and a rituximab product* (*see Appendix B for rituximab products*);

b. Cyclophosphamide*, doxorubicin*, prednisone, and a rituximab product* (*see Appendix B for rituximab products*);

**Prior authorization may be required for bendamustine, cyclophosphamide, doxorubicin and rituximab products*

6. Request meets one of the following (a or b):*
   a. Dose does not exceed 1.8 mg/kg on Day 1 of a 21-day cycle, for a maximum of 6 cycles;
   b. Dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (*prescriber must submit supporting evidence*).

   **Prescribed regimen must be FDA-approved or recommended by NCCN.*

Approval duration: 6 months (*medical justification supports requests for cycles beyond 6)*

B. High-Grade B-cell Lymphoma (must meet all)**:**

1. Diagnosis of previously untreated HGBL;
2. Prescribed by or in consultation with an oncologist or hematologist;
3. Age ≥ 18 years;
4. Member is not a candidate for allogeneic or autologous stem cell transplant;
5. Member has an International Prognostic Index score ≥ 2
6. Polivy is prescribed as a single agent or in combination with cyclophosphamide*, doxorubicin*, prednisone, and a rituximab product* (*see Appendix B for rituximab products*);

   **Prior authorization may be required for cyclophosphamide, doxorubicin, and rituximab products*
7. Request meets one of the following (a or b):*
   a. Dose does not exceed 1.8 mg/kg on Day 1 of a 21-day cycle, for a maximum of 6 cycles;
   b. Dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (prescriber must submit supporting evidence).

   **Prescribed regimen must be FDA-approved or recommended by NCCN.*

Approval duration: 6 months (*medical justification supports requests for cycles beyond 6*)

C. NCCN Recommended Uses (off-label) (must meet all)**:**

1. Diagnosis of one of the following (a, b, c, d, or e):
   a. Follicular lymphoma (FL) (grade 1-2);
   b. Mantle cell lymphoma;
   c. Monomorphic post-transplant lymphoproliferative disorder (B-cell type);
   d. One of the following AIDS-related B-cell lymphoma subtypes (i, ii, or iii):
      i. AIDS-related DLBCL;
      ii. Primary effusion lymphoma;
      iii. HHV8-positive diffuse large B-cell lymphoma, NOS;
      iv. AIDS-related plasmablastic lymphoma;
   e. Histologic transformation of nodal marginal zone lymphoma to diffuse large B-cell lymphoma;

2. Prescribed by or in consultation with an oncologist or hematologist;
3. Age ≥ 18 years;
4. For requests other than FL grade 1-2, member is not a candidate for allogeneic or autologous stem cell transplant;
5. Member has received ≥ 1 prior therapy (*see Appendix B*);
6. Polivy is prescribed as a single agent or in combination with one of the following regimens (a or b):
   a. Bendamustine* and/or a rituximab product* (*see Appendix B for rituximab products*);
   b. Cyclophosphamide*, doxorubicin*, prednisone, and a rituximab product* (*see Appendix B for rituximab products*);

   **Prior authorization may be required for bendamustine, cyclophosphamide, doxorubicin and rituximab products*
7. Dose is within FDA maximum limit for any FDA-approved indication or is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (*prescriber must submit supporting evidence*).*

   **Prescribed regimen must be FDA-approved or recommended by NCCN*

Approval duration: 6 months (*medical justification is required for requests for more than 6 cycles*)

D. Other diagnoses/indications (must meet 1 or 2)**:**

1. If this drug has recently (within the last 6 months) undergone a label change (e.g., newly approved indication, age expansion, new dosing regimen) that is not yet reflected in this policy, refer to LA.PMN.255
2. If the requested use (e.g., diagnosis, age, dosing regimen) is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized) AND criterion 1 above does not apply, refer to the off-label use policy for the relevant line of business: LA.PMN.53 for Medicaid.

II. Continued Therapy

A. All Indications in Section I (must meet all)**:**

1. Currently receiving medication via Louisiana Healthcare Connections benefit, or documentation supports that member is currently receiving Polivy for a covered indication and has received this medication for at least 30 days;
2. Member is responding positively to therapy;
3. Member meets one of the following (a or b):
   a. Member has received < 6 cycles of Polivy;
   b. Member has received less than the number of cycles recommended by NCCN for the covered indication;
4. If request is for a dose increase, request meets one of the following (a or b):*
   a. New dose does not exceed 1.8 mg/kg on Day 1 of a 21-day cycle, for a maximum of 6 cycles;
   b. New dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (*prescriber must submit supporting evidence*).

   **Prescribed regimen must be FDA-approved or recommended by NCCN.*

Approval duration: 12 months (*medical justification supports requests for cycles beyond 6*)

B. Other diagnoses/indications (must meet 1 or 2)**:**

1. If this drug has recently (within the last 6 months) undergone a label change (e.g., newly approved indication, age expansion, new dosing regimen) that is not yet reflected in this policy, refer to LA.PMN.255
2. If the requested use (e.g., diagnosis, age, dosing regimen) is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized) AND criterion 1 above does not apply, refer to the off-label use policy for the relevant line of business: LA.PMN.53 for Medicaid.

III. Diagnoses/Indications for which coverage is NOT authorized:

A. Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off label use policies – LA.PMN.53 for Medicaid.

IV. Appendices/General Information

Appendix A: Abbreviation/Acronym Key

DLBCL: diffuse large B-cell lymphoma
FDA: Food and Drug Administration
FL: follicular lymphoma
HGBL: high-grade B-cell lymphoma
NCCN: National Comprehensive Cancer NetworkNOS: not otherwise specified
IPI: International Prognostic Index score

Appendix B: Therapeutic Alternatives

This table provides a listing of preferred alternative therapy recommended in the approval criteria. The drugs listed here may require prior authorization.

Drug Name	Dosing Regimen	Dose Limit/ Maximum Dose
Rituximab Products		
Rituxan® (rituximab), Truxima® (rituximab-abbs), Rituxan Hycela® (rituximab-hyaluronidase)	Varies	Varies
DLBCL *Regimen examples (NCCN)*		
bendamustine ± rituximab	Varies	Varies
CEPP (cyclophosphamide, etoposide, prednisone, procarbazine) ± rituximab	Varies	Varies
lenalidomide ± rituximab	Varies	Varies
HGBL *Regimen examples (NCCN)*		
DA-EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin + rituximab)	Varies	Varies
RCHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone)	Varies	Varies
FL (grade 1-2) *Regimen examples (NCCN)*		

Drug Name	Dosing Regimen	Dose Limit/ Maximum Dose
Anthracycline- or anthracenedione-based regimens: CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) + obinutuzumab or rituximab CVP (cyclophosphamide,vincristine, prednisone) + obinutuzumab or rituximab	Varies	Varies
RCHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone)	Varies	Varies
Mantle Cell Lymphoma *Regimen examples (NCCN)*		
RDHA (rituximab, dexamethasone, cytarabine) + platinum (carboplatin, ciplatin, or oxaliplatin)	Varies	Varies
VR-CAP (bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone)	Varies	Varies
Post-Transplant Lymphoproliferative Disorder *Regimen examples (NCCN)*		
CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) + obinutuzumab or rituximab	Varies	Varies
CVP (cyclophosphamide,vincristine, prednisone) + obinutuzumab or rituximab	Varies	Varies
AIDS-related B-Cell Lymphoma *Regimen examples (NCCN)*		
R-EPOCH (rituximab, etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin)	Varies	Varies
CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) + rituximab	Varies	Varies
Histologic Transformation of Nodal Marginal Zone Lymphoma to DLBCL *Regimen examples (NCCN)*		
RCHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone)	Varies	Varies

Therapeutic alternatives are listed as Brand name® (generic) when the drug is available by brand name only and generic (Brand name®) when the drug is available by both brand and generic.

Appendix C: Contraindications/Boxed Warnings
None reported

Appendix D: DLBCL Subtypes per the National Comprehensive Cancer Network (NCCN)
- DLBCL, NOS (*FDA-approved use*)
- DLBCL coexistent with follicular lymphoma of any grade
- DLBCL coexistent with gastric MALT lymphoma
- DLBCL coexistent with nongastric MALT lymphoma
- Follicular lymphoma grade 3
- Intravascular large B-cell lymphoma
- DLBCL associated with chronic inflammation
- ALK-positive LBCL

- EBV-positive DLBCL, NOS
- T-cell/histiocyte-rich large B-cell lymphoma
- LBCL with IRF4/MUM1 rearrangement
- Double expressor DLBCL
- Primary mediastinal LBCL
- Gray zone lymphoma
- High-grade B-cell lymphomas with translocations of MYC and BCL2 and/or BCL6
- High-grade B-cell lymphomas, NOS
- Primary cutaneous DLBCL

V. Dosage and Administration

Indication	Dosing Regimen	Maximum Dose
DLBCL	1.8 mg/kg IV over 90 minutes every 21 days for 6 cycles in combination with a rituximab product, cyclophosphamide, doxorubicin, and prednisone. *(Administer POLIVY, cyclophosphamide, doxorubicin, and a rituximab product in any order on Day 1 after the administration of prednisone. Prednisone is administered on Days 1–5 of each cycle.)* OR 1.8 mg/kg IV over 90 minutes every 21 days for 6 cycles in combination with bendamustine and a rituximab product. *(Administer Polivy, bendamustine, and rituximab product in any order on Day 1 of each cycle.)* • Bendamustine: The recommended dose of bendamustine is 90 mg/m^2/day IV on Day 1 and 2 when administered with Polivy and a rituximab product. • Rituximab product: The recommended dose of rituximab product is 375 mg/m^2 IV on Day 1 of each cycle.	1.8 mg/kg (Polivy)
HGBL	1.8 mg/kg IV over 90 minutes every 21 days for 6 cycles in combination with a rituximab product, cyclophosphamide, doxorubicin, and prednisone. *(Administer POLIVY, cyclophosphamide, doxorubicin, and a rituximab product in any order on Day 1 after the administration of prednisone. Prednisone is administered on Days 1–5 of each cycle.)*	1.8 mg/kg (Polivy)

VI. Product Availability

Single-dose vial for injection after reconstitution: 30 mg, 140 mg

VII. References

1. Polivy Prescribing Information. South San Francisco, CA: Genentech, Inc.; April 2023. Available at: https://www.gene.com/download/pdf/polivy_prescribing.pdf. Accessed July 20, 2023.
2. National Comprehensive Cancer Network Drugs and Biologics Compendium. Available at: http://www.nccn.org/professionals/drug_compendium. Accessed May 2, 2022.
3. National Comprehensive Cancer Network. B-Cell Lymphomas Version 3.2022. Available at: https://www.nccn.org/professionals/physician_gls/pdf/b-cell.pdf. Accessed May 2, 2022.

Coding Implications

Codes referenced in this clinical policy are for informational purposes only. Inclusion or exclusion of any codes does not guarantee coverage. Providers should reference the most up-to-date sources of professional coding guidance prior to the submission of claims for reimbursement of covered services.

HCPCS Codes	Description
J9309	Injection, polatuzumab vedotin-piiq (Polivy)

Reviews, Revisions, and Approvals	Date	LDH Approval Date
Policy created.	05.09.23	
Added additional approved indication and criteria for previously untreated HGBL. Added additional approved dosing regimen for DLBCL. Added HGBL section to the Dosing and Administration table. Reviewed and updated references.	07.20.23	

Important Reminder

This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. LHCC makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering

benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions, and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable LHCC administrative policies and procedures.

This clinical policy is effective as of the date determined by LHCC. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. LHCC retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment, or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care and are solely responsible for the medical advice and treatment of members. This clinical policy is not intended to recommend treatment for members. Members should consult with their treating physician in connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom LHCC has no control or right of control. Providers are not agents or employees of LHCC.

This clinical policy is the property of LHCC. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members, and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members and their representatives agree to be bound by such terms and conditions by providing services to members and/or submitting claims for payment for such services.